Trial Profile
Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ChangHER-SC
- 16 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Jul 2018.
- 30 Mar 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2018.